A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Inclusion Criteria Patients must have: * Documented diagnosis of HIV infection with plasma HIV-RNA greater than or equal to 10,000 copies/ml. * Life expectancy of at least 12 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Current bilateral peripheral neuropathy greater than or equal to Grade 2. * Proven or suspected acute hepatitis due to any cause. * Recurrent episodes of moderate to severe diarrhea, or vomiting lasting for more than 4 days within 3 months prior to dosing. * Hypersensitivity to any component of the formulation of efavirenz, stavudine, or lamivudine. * Any clinically significant laboratory findings obtained during the screening evaluation (see laboratory values). * Any clinically significant disease (other than HIV infection) or clinically significant findings found during the screening of medical history or physical examination. * Any malignancy that requires systemic therapy. * Any active AIDS-defining opportunistic infection or disease. Concurrent Medication: Excluded: Astemizole, cisapride, clarithromycin, ketoconazole, itraconazole, midazolam, rifabutin, rifampin, terfenadine, thalidomide, triazolam, vincristine, zalcitabine or any medications contraindicated for concomitant use with stavudine or lamivudine as described in the current information package insert. Patients with the following prior conditions are excluded: * History of acute or chronic pancreatitis. * A life expectancy of less than 12 months. * Difficulty swallowing capsules/tablets. * Inability to communicate effectively with study personnel. Prior Medication: Excluded: * Any other experimental drug within 30 days of introducing study treatment. * Vaccination within 3 weeks of screening visit. * Any prior antiretroviral therapy. * Interferon started within 30 days of initiating study treatment. Risk Behavior: Excluded: Current alcohol or illicit drug use which interferes with patient's ability to follow study regimen.